Recent Publications
Werner, B., Sjoquist, K.M., Espinoza, D., Yip, S., Chang, G., Cummins, M.M., Mileshkin, L., Ananda, S., Shannon, C., Friedlander, M., Warton, K., Ford, C.E. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. 2024 Feb. visit
Fisher, T., Powell, E., Yuwono, N., Ford, C.E., Warton, K. Circulating cell-free DNA is elevated in postmenopausal compared with pre- and perimenopausal women. 2024 Mar. visit
Cortesi, M., Liu, D., Yee, C., Marsh, D.J., Ford, C.E. A comparative analysis of 2D and 3D experimental data for the identification of the parameters of computational models. 2023 Sep 22. visit
Yuwono, N. L., Alonso, A., Abbott, J., Houshdaran, S., Henry, C. E., Rodgers, R., Ford, C. E., & Warton, K. Circulating cell-free endometrial DNA level is unaltered during menstruation and in endometriosis. Human Reproduction. 2022 Sep 27. visit
Yuwono NL, Boyd MAA, Henry CE, Werner B, Ford CE, and Warton K. Circulating Cell-Free DNA Undergoes Significant Decline in Yield after Prolonged Storage Time in Both Plasma and Purified Form. Clin Chem Lab Med. 2022 May 31. visit
Fisher T, Ford CE, Warton K. Recovery Efficiency of Cell-Free DNA After Bisulfite Conversion. Clinical Chemistry. 2022 Jul 20. visit
Liu D, Kaufmann GF, Breitmeyer JB, Dickson KA, Marsh DJ, Ford CE. The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11 visit
Werner B, Warton K, Ford CE. Transcending Blood—Opportunities for Alternate Liquid Biopsies in Oncology. Cancers. 2022 visit
Alonso A, Yuwono NL, Houshdaran S, Abbott J, Rodgers R, Ford CE, Warton K. Comparison of total and endometrial circulating cell-free DNA in women with and without endometriosis. Reproductive BioMedicine Online. 2021 Nov 13. visit
Liu D, Sharbeen G, Phillips P, Ford CE. ROR1 and ROR2 expression in pancreatic cancer. BMC cancer. 2021. visit
Yuwono NL, Warton K, Ford CE. The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma. Elife. 2021. visit.
Joshi N, Liu D, Marsh D, Dickson KA, Ford C, Stenzel MH. An organotypic model of high-grade serous ovarian cancer to test the anti-metastatic potential of ROR2 targeted Polyion complex nanoparticles. Journal of Materials Chemistry B. 2021. visit
Werner B, Yuwono N, Duggan J, Liu D, David C, Srirangan S, Provan P, DeFazio A, Arora V, Farrell R, Lee YC, Warton K, Ford C., Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecologic Oncology. 2021 Jul 5. visit
Yuwono NL, Henry CE, Ford CE, Warton K. Total and endothelial cell-derived cell-free DNA in blood plasma does not change during menstruation. PloS one. 2021 Apr. visit
Hagstrom AD, Yuwono N, Warton K, Ford CE. Sex bias in cohorts included in sports medicine research. Sports Medicine. 2021 Jan. visit
Liu D, Enriquez L, Ford CE. ROR2 Is Epigenetically Regulated in Endometrial Cancer. Cancers. 2021 Jan. visit
Liu D, Gunther K, Enriquez LA, Daniels B, O’Mara TA, Tang K, Spurdle AB, Ford CE. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target. Scientific reports. 2020 Aug. visit
Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. British journal of cancer. 2020 Jul. visit
Werner B, Yuwono NL, Henry C, Gunther K, Rapkins RW, Ford CE, Warton K. Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight. PloS one. 2019 Oct. visit
Lu M, Henry CE, Lai H, Khine YY, Ford CE, Stenzel MH. A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles. Biomaterials science. 2019. visit
Henry CE, Llamosas E, Daniels B, Coopes A, Tang K, Ford CE. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer. Gynecologic oncology. 2018 Mar. visit